The report is available in English with a Dutch summary - KCE

More documents

Recommendations

Info

24 Plasma KCE Reports 120 Figure 2: Demographic prospects in Germany 2006-2031 (Age distribution) Source: German Federal Statistical Office Divergence between these both trends has been clearly highlighted by Robert Koch Institute as an ageing population means an increase of potential recipients. On the long term, it could raise major problems in terms of supply/demand. In order to prevent shortfalls in plasma supply, it is clear that the number of donors should be raised over the whole population of potential donors (ie 18-68). Emphasis should also be laid on retention of donors. Private centres and industry-driven centres will face major difficulties unless they recruit a much large number of donors in higher age groups (above 35) than they do today. Further information on donation campaign and demographic issues in Appendix “Germany” Key points • Maximisation of individual donation volume is one of the key issues of ongoing studies in Germany. • Considering plasma delivered for fractionation, plasmapheresis plays an important role, and is largely performed by private centres. • Plasma donors’ profile is quite specific: younger, more-educated, less involved in professional life, and less often married. • “Real World” communication campaigns and practical follow-up of donors with modern techniques are of key importance to improve retention of donors. Interface with the education system is also of paramount importance. • Great attention is paid to the demographic dimension to adjust recruitment and retention policy accordingly.
KCE Reports 120 Plasma 25 2.1.3.2 Plasma collection in France Historical Background For historical reasons, collection and fractionation activities have been clearly split between two different institutions: • Etablissement Français du Sang (EFS) for collection and vigilance activities (and other specific activities / see below) • Laboratoire Français de Fractionnement et de Biotechnologie (LFB) for fractionation activities, marketing of plasma-derived products, and Biotechnology R&D. In their own respective fields of activity, each of these institutions enjoys a monopoly. For practical reasons, both institutions have to work in connection under the supervision of public authorities. However, they are matters for different legal statuses. Safety and security requirements The AFSSAPS – Agence Française de Sécurité Sanitaire des Produits de Santé French Agency for the Safety of Health Products (Decision of 6 November 2006) is in charge of seting out security rules, defining and disseminating best practices, but also ensuring propoer monitoring of blood and plasma-derived products (see further). EU legal requirements are obviously applicable in the field of blood donation, quality and safety, as described above in the report Legal status and missions of the Etablissement Français du Sang -EFS LEGAL STATUS The EFS has been created in 2000, is a public-law body and comprises one national head office and 17 regional branches. Key members of its Board of Administration are representatives of the Department of Health, Ministry of Finance, and Ministry of Research. Representatives of the Health Care Insurance Funds are also members of the Board. While being a public institution one must notice that the EFS does not receive any public subsidy (most of its resources stem from the sale of labile products to hospitals) See website: http://www.dondusang.net/rewrite/heading/1.htm?idRubrique=1) . THE MISSIONS OF THE EFS These missions have been set out by the French legislation as follows: • Collection of blood and plasma: See also Appendix “France” on collection issues • Ensuring self-sufficiency • Vigilance activities: ensuring actual application of safety and quality requirements, especially good practices set out by the AFSSAPS mentioned above. • Implementing highly-skilled technical and research activities in connection with blood/tissue: stem cells bank, bone marrow transplants, placental blood, etc… • Delivery of labile products to hospitals for transfusion purposes • Delivery of plasma to the LFB for fractionation purposes (official delivery targets) • International cooperation activities
Page 1 and 2: Hoe zelfvoorziening in stabiele pla
Page 3 and 4: Hoe zelfvoorziening in stabiele pla
Page 5 and 6: KCE Reports 120A Plasma i VOORWOORD
Page 7 and 8: KCE Reports 120A Plasma iii METHODO
Page 9 and 10: KCE Reports 120A Plasma v Elke lite
Page 11 and 12: KCE Reports 120A Plasma vii AANBEVE
Page 13 and 14: KCE Reports 120 Plasma 1 Scientific
Page 15 and 16: KCE Reports 120 Plasma 3 GLOSSARY A
Page 17 and 18: KCE Reports 120 Plasma 5 1 INTRODUC
Page 19 and 20: KCE Reports 120 Plasma 7 Focus: sta
Page 21 and 22: KCE Reports 120 Plasma 9 Two techni
Page 23 and 24: KCE Reports 120 Plasma 11 Therefore
Page 25 and 26: KCE Reports 120 Plasma 13 FRENCH-SP
Page 27 and 28: KCE Reports 120 Plasma 15 Number of
Page 29 and 30: KCE Reports 120 Plasma 17 Table 4:
Page 35: KCE Reports 120 Plasma 23 Role of t
Page 39 and 40: KCE Reports 120 Plasma 27 • 73% o
Page 41 and 42: KCE Reports 120 Plasma 29 2.2 TRANS
Page 43 and 44: KCE Reports 120 Plasma 31 Figure 6:
Page 45 and 46: KCE Reports 120 Plasma 33 GEOGRAPHI
Page 47 and 48: KCE Reports 120 Plasma 35 It is sur
Page 49 and 50: KCE Reports 120 Plasma 37 Plasma fr
Page 51 and 52: KCE Reports 120 Plasma 39 2.3 LIMIT
Page 55 and 56: KCE Reports 120 Plasma 43 3.2 INDIC
Page 57 and 58: KCE Reports 120 Plasma 45 Subcutane
Page 61 and 62: KCE Reports 120 Plasma 49 3.2.2 Evi
Page 63 and 64: KCE Reports 120 Plasma 51 Search re
Page 65 and 66: KCE Reports 120 Plasma 53 CIDP IG i
Page 67 and 68: KCE Reports 120 Plasma 55 • IG re
Page 69 and 70: KCE Reports 120 Plasma 57 Solid org
Page 71 and 72: KCE Reports 120 Plasma 59 A Cochran
Page 73 and 74: KCE Reports 120 Plasma 61 • In ch
Page 75 and 76: KCE Reports 120 Plasma 63 Two small
Page 77 and 78: KCE Reports 120 Plasma 65 was lower
Page 79 and 80: KCE Reports 120 Plasma 67 Three RCT
Page 81 and 82: KCE Reports 120 Plasma 69 Severe se
Page 83 and 84: KCE Reports 120 Plasma 71 The analy
Page 85 and 86: KCE Reports 120 Plasma 73 3.3.1.2 T
Page 87 and 88:
KCE Reports 120 Plasma 75 Figure 7:
Page 89 and 90:
KCE Reports 120 Plasma 77 Figure 10
Page 91 and 92:
KCE Reports 120 Plasma 79 Table 30:
Page 93 and 94:
KCE Reports 120 Plasma 81 Table 36:
Page 95 and 96:
KCE Reports 120 Plasma 83 • For b
Page 97 and 98:
KCE Reports 120 Plasma 85 3.3.2.6 L
Page 99 and 100:
KCE Reports 120 Plasma 87 • The p
Page 101 and 102:
KCE Reports 120 Plasma 89 In Belgiu
Page 103 and 104:
KCE Reports 120 Plasma 91 Multifoca
Page 105 and 106:
KCE Reports 120 Plasma 93 Based on
Page 107 and 108:
KCE Reports 120 Plasma 95 Disease /
Page 109 and 110:
KCE Reports 120 Plasma 97 3.3.4 Exp
Page 111 and 112:
KCE Reports 120 Plasma 99 Figure 12
Page 113 and 114:
KCE Reports 120 Plasma 101 Key poin
Page 115 and 116:
KCE Reports 120 Plasma 103 Key poin
Page 117 and 118:
KCE Reports 120 Plasma 105 • Conf
Page 119 and 120:
KCE Reports 120 Plasma 107 As far a
Page 121 and 122:
KCE Reports 120 Plasma 109 Followin
Page 123 and 124:
KCE Reports 120 Plasma 111 4.3 HOW
Page 125 and 126:
KCE Reports 120 Plasma 113 Improvin
Page 127 and 128:
KCE Reports 120 Plasma 115 4.3.2 St
Page 129 and 130:
KCE Reports 120 Plasma 117 4.4 CONC
Page 131 and 132:
KCE Reports 120 Plasma 119 FAVOURIN
Page 133 and 134:
KCE Reports 120 Plasma 121 APPENDIX
Page 135 and 136:
KCE Reports 120 Plasma 123 For othe
Page 137 and 138:
KCE Reports 120 Plasma 125 Table 48
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
KCE Reports 120 Plasma 131 Distribu
Page 145 and 146:
KCE Reports 120 Plasma 133 • Conv
Page 147 and 148:
Page 149 and 150:
KCE Reports 120 Plasma 137 6 REFERE
Page 151 and 152:
KCE Reports 120 Plasma 139 41. Pruz
Page 153 and 154:
KCE Reports 120 Plasma 141 82. Comi
Page 155 and 156:
KCE Reports 120 Plasma 143 123. Cre
Page 157 and 158:
KCE Reports 120 Plasma 145 165. Cua
Page 159 and 160:
This page is left intentionally bla
Page 161 and 162:
KCE reports 1. Effectiviteit en kos
Page 163 and 164:
73. Financiering van het zorgprogra
show all

The report is available in English with a Dutch summary - KCE

Create successful ePaper yourself

Delete template?

Save as template?